Lipid-Lowering Therapy in Persons With Chronic Kidney Disease
Authors:
- 21 August 2012
- journal article
- review article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 157 (4) , 251-262
Abstract
Lipid-lowering therapy is not widely used in persons with chronic kidney disease (CKD) despite a high burden of dyslipidemia and cardiovascular disease in this population. To synthesize evidence examining the effect of lipid-lowering therapy on clinical outcomes in persons with CKD. MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from January 2000 through November 2011. Randomized, controlled trials (RCTs) comparing lipid-lowering therapy with control treatment in persons with CKD, including subgroup analyses of trials in the general population. Abstracts were screened and data were extracted on study methodology, population, interventions, cardiovascular and kidney outcomes, and adverse events. Data were extracted by one author and confirmed by another. Study quality was determined by consensus. Random-effects model meta-analyses were performed. 18 RCTs, all in adults, met the eligibility criteria. Five RCTs involved CKD populations, and 13 were CKD subgroup analyses from trials in the general population. Sixteen RCTs examined statins, and 2 examined statins plus ezetimibe. Lipid-lowering therapy does not improve kidney outcomes but decreases the risk for cardiac mortality (pooled risk ratio [RR] from 6 trials, 0.82 [95% CI, 0.74 to 0.91]; P< 0.001), cardiovascular events (including revascularization) (pooled RR from 9 trials, 0.78 [CI, 0.71 to 0.86]; P< 0.001), and myocardial infarction (pooled RR from 9 trials, 0.74 [CI, 0.67 to 0.81]; P< 0.001). Significant benefit was also seen for all-cause mortality but was limited by a high degree of heterogeneity. No benefit was found for other cardiovascular outcomes. Rates of adverse events were similar between intervention and comparator groups. Lack of data in children, heterogeneity among reviewed studies, and the possibility of selective reporting of outcomes and adverse events. Lipid-lowering therapy decreases cardiac death and atherosclerosis-mediated cardiovascular events in persons with CKD.Keywords
This publication has 46 references indexed in Scilit:
- AHRQ Series Paper 5: Grading the strength of a body of evidence when comparing medical interventions—Agency for Healthcare Research and Quality and the Effective Health-Care ProgramJournal of Clinical Epidemiology, 2010
- Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive ProteinJACC, 2010
- Pravastatin and cardiovascular risk in moderate chronic kidney diseaseAtherosclerosis, 2009
- Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney DiseaseMayo Clinic Proceedings, 2008
- Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney DiseaseJACC, 2008
- Cardiovascular Disease Risk Factors in Chronic Kidney DiseaseArchives of internal medicine (1960), 2006
- Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy)The American Journal of Cardiology, 2005
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Atherosclerosis Supplements, 2004
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Effect of the Statistical Significance of Results on the Time to Completion and Publication of Randomized Efficacy TrialsJAMA, 1998